by Juliette Boynton | Jan 1, 2016 | Briefings, UK
In a second medical use patent to the “Use of tomoxetine for the manufacture of a medicament for treating attention-deficit/hyperactivity disorder”, EP(UK) 0721777, no data was provided to support the claimed invention. Actavis sought to revoke the patent on the...
by Alex Bajjon | Jan 1, 2016 | Briefings, UK
Consideration is generally held to be something of value exchanged between parties in order for a contract to be valid and enforceable. Agreements without consideration are deemed to be mere gratuitous promises and are not enforceable by law. As a standard term, most...
by David Eyre | Jan 1, 2016 | US & International
The origin of the PTE system flows from a desire to compensate those who have invested time and resources in making or finding new medical products for the additional burden of gaining regulatory approval for that product. Thus, originally, the PTE provisions were...
by | Oct 1, 2015 | Briefings, UK
Warner-Lambert is proprietor of a European patent (EP 0641330) which claims the compound pregabalin (via compound per se claims). The Supplementary Protection Certificate (SPC) was (surprisingly) allowed to lapse in October 2013 for non-payment of fees resulting in...
by Sean Hughes | Sep 1, 2015 | EPO
Undisclosed disclaimer – disclaimed features are not disclosed in original application. Disclosed disclaimer – disclaimed features are disclosed as an embodiment of the invention. EPO decision G1/03 sets out a limited number of circumstances in which undisclosed...
Recent Comments